Table 2.
Predicting factors of antibody production
| Parameters | Univariate | Multivariate | ||
|---|---|---|---|---|
| OR (95%CI) | p value | OR (95%CI) | p value | |
| S-IgG positivity at T2 | ||||
| Age ≥65 | NA (complete separation) | – | – | – |
| Lymphopenia (<1000/μL) | 0.26 (0.10–0.65) | 0.004 | 0.37 (0.14–0.99) | 0.048 |
| ISS stage III | 1.02 (0.36–2.9) | 0.97 | – | – |
| Polyclonal IgG (<550 mg/dL) | 0.29 (0.10–0.83) | 0.021 | 0.40 (0.12–1.3) | 0.14 |
| High-risk CAs | 0.48 (0.15–1.5) | 0.21 | – | – |
| Treatment response PR or less | 0.25 (0.09–0.67) | 0.059 | 0.24 (0.08–0.74) | 0.013 |
| Anti-CD38 antibody use | 0.339 (0.14–0.85) | 0.021 | 0.32 (0.11–0.90) | 0.031 |
| IMiDs use | 0.497 (0.19–1.33) | 0.16 | – | – |
| Elotuzumab use | 2.01 (0.25–16.0) | 0.51 | – | – |
| IVIg use | 0.37 (0.12–1.14) | 0.083 | 0.69 (0.19–2.5) | 0.58 |
| Clinically protective titer at T2 | ||||
| Age ≥65 | 0.44 (0.18–1.06) | 0.066 | 0.36 (0.13–0.99) | 0.048 |
| Lymphopenia (<1000/μL) | 0.31 (0.15–0.65) | 0.002 | 0.31 (0.13–0.70) | 0.005 |
| ISS stage III | 0.971 (0.49–1.7) | 0.77 | – | – |
| Polyclonal IgG (<550 mg/dL) | 0.30 (0.16–0.55) | < 0.001 | 0.29 (0.14–0.58) | < 0.001 |
| High-risk CAs | 1.5 (0.68–3.2) | 0.33 | – | – |
| Treatment response PR or less | 0.31 (0.11–0.85) | 0.023 | 0.33 (0.10–1.04) | 0.058 |
| Anti-CD38 antibody use | 0.42 (0.23–0.79) | 0.006 | 0.58 (0.24–1.4) | 0.22 |
| IMiDs use | 0.34 (0.18–9.61) | 0.004 | 0.26 (0.12–0.54) | < 0.001 |
| Elotuzumab use | 0.70 (0.23–2.1) | 0.53 | – | – |
| IVIg use | 0.32 (0.10–0.97) | 0.045 | 0.41 (0.11–1.5) | 0.18 |
CAs cytogenetic abnormality, IMiDs immunomodulatory drugs, ISS international staging system, IVIg intravenous immunoglobulin, NA not available, OR odds ratio, PR partial response